[324 Pages Report] The global endoscopic retrograde cholangiopancreatography (ERCP) devices market is estimated to reach US$ 1.5 Billion in 2022, and anticipated to reach US$ 2.8 Bn by 2032, owing to an increase in cancer cases across the globe. As per FMI, the endoscopic retrograde cholangiopancreatography (ERCP) devices market is likely to exhibit the growth at a CAGR of 6.2% during the forecast period from 2022 to 2032.
| Report Attribute | Details |
|---|---|
| Endoscopic Retrograde Cholangiopancreatography Devices Market Anticipated Forecast Value (2022) | US$ 1.5 Billion |
| Endoscopic Retrograde Cholangiopancreatography Devices Market Anticipated Forecast Value (2032) | US$ 2.8 Billion |
| Endoscopic Retrograde Cholangiopancreatography Devices Market Projected Growth Rate (2022 to 2032) | 6.2% CAGR |
Endoscopic retrograde cholangiopancreatography (ERCP) device is a mixed fluoroscopic and endoscopic procedure wherein an endoscope is introduced into the second part of the duodenum, therefore enabling other tools to be incorporated into the biliary and pancreatic ducts through the key duodenal papilla.
ERCP devices use an amalgamation of luminal endoscopy and fluoroscopic imaging to diagnose and treat disorders related to pancreaticobiliary. These devices make use of a side-view duodenoscopy and are introduced through the esophagus and stomach into the stomach section of the duodenum. Endoscopic retrograde cholangiopancreatography (ERCP) devices are mainly used for extracting samples of cells and tissues or for treating blocked bile or pancreatic duct.
Substitutes for ERCP devices consist of magnetic resonance cholangiopancreatography devices and computed tomography machines, and therefore there is a strong demand for endoscopic retrograde cholangiopancreatography devices in the coming years.
The market is majorly driven by increasing cancer cases, added investments by governments and healthcare facilities to enhance endoscopy research, rising adoption of minimally invasive procedures and surgeries, and major hospitals investing in improved endoscopy research.
The COVID-19 pandemic has adversely affected all industries across the globe. Surgeons and patients who visited hospitals for varied treatments were at a higher risk of getting infected by the virus. Several gastrointestinal procedures were halted or stopped, and this led to reduced device-based treatments such as ERCP.
Based on research, the pandemic considerably decreased ERCP procedures. Approximately 50 per cent of endoscopy procedures were annulled in several primary hospitals across Germany. In the UK and worldwide, the success rate diminished owing to restrictions on endoscopic services.
All these factors adversely affected the endoscopic retrograde cholangiopancreatography (ERCP) devices market. Furthermore, the endoscopy procedure is believed to be a procedure that generates aerosol; this possessed as a threat and risk of transmission to healthcare professionals.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The growth of the Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices market is attributed to the rising number of cancer cases and a paradigm shift toward minimally invasive procedures.
Several other factors such as an increase in incidences of chronic biliary and gastrointestinal disorders like colitis, Barrett’s disease, Crohn’s disease, biliary disease, pancreatitis, gastroesophageal reflux disorder (GERD), peptic ulcer disease, liver disease, and inflammatory bowel disease, support the demand for endoscopic retrograde cholangiopancreatography (ERCP) devices and thereby contribute to the higher growth rate of the ERCP devices market.
There is a swift rise in the frequencies of benign tumours of the pancreas and liver along with the rising geriatric population, which contributes to the market growth of endoscopic retrograde cholangiopancreatography (ERCP) devices.
Additionally, there is more awareness pertaining to the devices which are used in ERCP for treating disorders. Currently, there is various ongoing research done towards safer use and enhanced efficiency of these endoscopic retrograde cholangiopancreatography (ERCP) devices. This, coupled with increasing government support for R&D, could fuel the market growth for endoscopic retrograde cholangiopancreatography (ERCP) devices throughout the forecast period
Amongst the economies across the world, the swiftest growing ones are Brazil, Russia, India, China, and South Africa (BRICS). As per the World Economic Forum, the developing economies attributed for nearly one-third of the worldwide expenditure in 2021.
Over half of the world’s population resides in China and India, and this makes their countries with the highest patient population. The fastest enhancements in healthcare infrastructure, rising burden of cancer, existence of flexible regulation, and speedy growth in medical tourism in these emerging countries promotes market players in the endoscopy equipment market to bloom their footprint in these countries.
Various manufacturers of endoscopy equipment are presently setting up their facilities in Latin America, Asia Pacific, and the Middle East. For instance, giants like Karl Storz have established their R&D and manufacturing facilities in these countries.
Moreover, in the developed regions, market saturation is observed. Therefore, in regions like Europe and North America, manufacturers are forced to focus more on emerging market in the future years. All these abovementioned are projected to render considerable growth opportunities for the ERCP market.
Principal Consultant
ERCP devices and procedures are expensive, and therefore the high costs pertaining to the treatment from ERCP are one of the key factors hampering the market growth and hence the demand for endoscopic retrograde cholangiopancreatography (ERCP) devices.
Also, the risks and side-effects of the treatment procedure like post-ERCP pancreatitis are anticipated to hinder the growth of the market during the forecast period. Furthermore, for several small-scale end users, these procure are not easily accessible and are not affordable.
Region-wise, North America's Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices market is projected to bloom considerably due to a greater number of research related to diagnostic imaging and improved R&D for novel upgraded ERCP devices.
In 2019, North America accounted for a larger market share owing to the well-established healthcare infrastructure in this region and the existence of key players and their product availability. Excess expenditure and enhanced healthcare infrastructure are projected to boost the Europe market for ERCP devices during the forecast period.
Nevertheless, Asia Pacific is said to garner higher CAGR since several governments of the countries from this region are focusing on investing in the development of healthcare infrastructure.
Also, increasing awareness about cholangiopancreatography procedures in Japan, China and India will promote the growth of the market in the Asia Pacific. Additionally, in 2021, China and Japan attributed for nearly 60% market share at the regional level, owing to increased cases of Gastrointestinal cancers in both these countries.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the most prominent companies in the global endoscopic retrograde cholangiopancreatography (ERCP) devices market are Olympus Corporation, Boston Scientific Corporation, CONMED Corporation, Cook Medical, Inc., Fujifilm Holdings Corporation, Hobbs Medical, Merit Medical Systems and, TeleMed Systems, Inc.
Recently, the manufacturers operating in the endoscopic retrograde cholangiopancreatography (ERCP) devices have been engaged in novel product launches, acquisitions, and partnerships, to gain considerable position in the market. For example, Fujifilm Holdings Corporation in March 2021 acquired the diagnostic imaging-related business of Hitachi Ltd., to make its healthcare business more robust.
| Report Attribute | Details |
|---|---|
| Growth rate | CAGR of 6.2% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD million, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | Disease Indication, Product Type, End User, Region |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | Olympus Corporation; Boston Scientific Corporation; CONMED Corporation; Cook Medical, Inc.; Hobbs Medical; Merit Medical Systems and; TeleMed Systems, Inc.; Fujifilm Holdings Corporation |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The global endoscopic retrograde cholangiopancreatography (ERCP) devices market is estimated to grow at a CAGR of 6.2% from 2022 to 2032.
North America is the key region accountable for highest revenue generation in this market.
Some of the key players in the market include Olympus Corporation, Boston Scientific Corporation, CONMED Corporation, Cook Medical, Inc., Hobbs Medical, Merit Medical Systems and, Fujifilm Holdings Corporation, TeleMed Systems, Inc.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Indication 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Disease Indication, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Disease Indication, 2022-2032 5.3.1. Gastroesophageal Reflux Disease 5.3.2. GI Cancer 5.3.3. Barrett's Esophagus 5.3.4. Bile Duct Diseases 5.3.5. Peptic Ulcer Disease 5.3.6. Crohn's Disease 5.3.7. Intestinal Pseudo-Obstruction and Ogilvie Syndrome 5.3.8. Other Disease Indications 5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017-2021 5.5. Absolute $ Opportunity Analysis By Disease Indication, 2022-2032 6. Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Product Type, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Product Type, 2022-2032 6.3.1. Sphincterotomes 6.3.2. Lithotripter 6.3.3. Endoscopes 6.3.4. Accessories 6.3.5. Stents 6.3.6. Cannulas 6.3.7. Forceps 6.3.8. Snares 6.3.9. Catheters 6.3.10. Guiding Wires 6.3.11. Balloons 6.3.12. Others (Baskets etc.) 6.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021 6.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032 7. Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By End User, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By End User, 2022-2032 7.3.1. Hospitals 7.3.2. Specialty Clinics 7.3.3. Diagnostic Laboratories 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 7.5. Absolute $ Opportunity Analysis By End User, 2022-2032 8. Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia & Pacific 8.3.6. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Disease Indication 9.2.3. By Product Type 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Disease Indication 9.3.3. By Product Type 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Mexico 10.2.1.2. Brazil 10.2.1.3. Rest of Latin America 10.2.2. By Disease Indication 10.2.3. By Product Type 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Disease Indication 10.3.3. By Product Type 10.3.4. By End User 10.4. Key Takeaways 11. Europe Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. U.K. 11.2.1.5. Spain 11.2.1.6. BENELUX 11.2.1.7. Russia 11.2.1.8. Rest of Europe 11.2.2. By Disease Indication 11.2.3. By Product Type 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Disease Indication 11.3.3. By Product Type 11.3.4. By End User 11.4. Key Takeaways 12. East Asia Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Disease Indication 12.2.3. By Product Type 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Disease Indication 12.3.3. By Product Type 12.3.4. By End User 12.4. Key Takeaways 13. South Asia & Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. ASEAN 13.2.1.3. Australia and New Zealand 13.2.1.4. Rest of South Asia & Pacific 13.2.2. By Disease Indication 13.2.3. By Product Type 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Disease Indication 13.3.3. By Product Type 13.3.4. By End User 13.4. Key Takeaways 14. MEA Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country 14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. Turkey 14.2.1.3. South Africa 14.2.1.4. Rest of MEA 14.2.2. By Disease Indication 14.2.3. By Product Type 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Disease Indication 14.3.3. By Product Type 14.3.4. By End User 14.4. Key Takeaways 15. Key Countries Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Disease Indication 15.1.2.2. By Product Type 15.1.2.3. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Disease Indication 15.2.2.2. By Product Type 15.2.2.3. By End User 15.3. Mexico 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Disease Indication 15.3.2.2. By Product Type 15.3.2.3. By End User 15.4. Brazil 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Disease Indication 15.4.2.2. By Product Type 15.4.2.3. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Disease Indication 15.5.2.2. By Product Type 15.5.2.3. By End User 15.6. Italy 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Disease Indication 15.6.2.2. By Product Type 15.6.2.3. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Disease Indication 15.7.2.2. By Product Type 15.7.2.3. By End User 15.8. U.K. 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Disease Indication 15.8.2.2. By Product Type 15.8.2.3. By End User 15.9. Spain 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Disease Indication 15.9.2.2. By Product Type 15.9.2.3. By End User 15.10. BENELUX 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Disease Indication 15.10.2.2. By Product Type 15.10.2.3. By End User 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Disease Indication 15.11.2.2. By Product Type 15.11.2.3. By End User 15.12. China 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Disease Indication 15.12.2.2. By Product Type 15.12.2.3. By End User 15.13. Japan 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Disease Indication 15.13.2.2. By Product Type 15.13.2.3. By End User 15.14. South Korea 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Disease Indication 15.14.2.2. By Product Type 15.14.2.3. By End User 15.15. India 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Disease Indication 15.15.2.2. By Product Type 15.15.2.3. By End User 15.16. ASEAN 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Disease Indication 15.16.2.2. By Product Type 15.16.2.3. By End User 15.17. Australia and New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Disease Indication 15.17.2.2. By Product Type 15.17.2.3. By End User 15.18. GCC Countries 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Disease Indication 15.18.2.2. By Product Type 15.18.2.3. By End User 15.19. Turkey 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Disease Indication 15.19.2.2. By Product Type 15.19.2.3. By End User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Disease Indication 15.20.2.2. By Product Type 15.20.2.3. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Disease Indication 16.3.3. By Product Type 16.3.4. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Olympus Corporation 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Boston Scientific Corporation 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. CONMED Corporation 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Cook Medical, Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Hobbs Medical 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Merit Medical Systems 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. TeleMed Systems, Inc. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Healthcare
March 2018
REP-GB-468
May 2024
333 pages
Healthcare
June 2016
REP-GB-1620
September 2023
333 pages
Explore Healthcare Insights
View Reports
Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market
